Inhalation Drug Delivery News

  1. eXmoor Pharma And Vaccine Developer Imophoron Sign Process Development Partnership 2/22/2023

    eXmoor pharma, the cell and gene therapy partner specializing in accelerating the manufacturing journey from research to patients and Imophoron, the developer of a novel, next generation thermostable vaccine platform, ADDomer, to combat present and future infectious diseases, today announce the signature of a strategic process development partnership that includes a future GMP manufacturing route.

  2. Catalent And Ethicann Sign Development And License Agreement For New Fast-Dissolve Cannabinoid-Based Treatments 1/12/2023

    Catalent, the global leader in enabling the development and supply of better treatments across multiple modalities, and Ethicann Pharmaceuticals Inc., a Canadian/U.S. specialty pharmaceutical company focused on the development of high-value cannabinoid drug therapies, today announced that the companies had executed a development and license agreement to develop Ethicann’s clinical drug pipeline using Catalent’s proprietary Zydis orally disintegrating tablet (ODT) technology.

  3. Formulated Solutions Signs Agreement To Acquire 455,000ft2 US FDA Approved Drug Production Site 12/19/2022

    Formulated Solutions, a Florida-based Contract Development and Manufacturing Organization (CDMO) supporting consumer-centric innovation, expert development, and cost-effective production of consumer healthcare solutions, announced an agreement to acquire a newly updated 455,000 ft2 FDA approved pharmaceutical liquids, semi solids, aerosol, BoV, and metered dose nasal spray production facility located in Cleveland, TN.

  4. Hovione And GEA Announce A Strategic Collaboration To Advance Continuous Tableting 12/14/2022

    Hovione and GEA today announced a strategic collaboration to advance Continuous Tableting. This partnership stemmed from a successful customer-supplier relationship spanning several years.

  5. Recipharm Invests In Its Single Dose Nasal Platform Capabilities 11/30/2022

    Recipharm, a global contract development and manufacturing organisation (CDMO), has announced that it is expanding its capabilities for its proprietary Unidose Xtra (single dose) nasal delivery platform.

  6. Aptar Pharma Announces Collaboration With TFF Pharmaceuticals 11/7/2022

    Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announced a collaboration with TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform.

  7. EpiVax Joins Intravacc, CEPI On Project To Develop Universal Betacoronavirus Vaccine 10/31/2022

    EpiVax, Inc. ("EpiVax") is pleased to announce participation in a new project with Intravacc, funded by CEPI (Coalition for Epidemic Preparedness Innovations), to develop universal vaccines for betacoronaviruses, including SARS-CoV-2.

  8. Micro-Sphere Expands HPAPI Capabilities At Swiss Site 10/24/2022

    Spray drying specialist and capsule filling service contract development and manufacturing organisation (CDMO) Micro-Sphere has invested over €5M to expand its GMP manufacturing capabilities at its facility in Monteggio, Switzerland.

  9. CEPI Partners With Intravacc To Develop An Intranasal, Broadly Protective Betacoronavirus Vaccine 10/6/2022

    CEPI, the Coalition for Epidemic Preparedness Innovations, and Dutch vaccine clinical development and manufacturing organization Intravacc, today announced the latest funding award under CEPI's US$200m program to advance the development of vaccines that provide broad protection against SARS-CoV-2 (including its variants) and other Betacoronaviruses.

  10. Transpire Bio Announces Second Agreement With Recipharm For The Development Of Two Additional Inhaled Medicines 9/29/2022

    Transpire Bio, a development-stage pharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, has today announced a second definitive agreement with Recipharm to develop TRB-3 and TRB-4, inhaled medicines for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD).